BTG International

What BTG International does

BTG International is a global healthcare company focused on interventional medicine, founded in 1948 and headquartered in London, United Kingdom. The company develops, manufactures, and commercializes medical devices and specialty pharmaceuticals used by interventional specialists across vascular, oncology, pulmonology, urology, and pain management. Its portfolio has been built substantially through acquisition, with eight disclosed transactions between 2005 and 2018 — including EKOS (ultrasound-assisted thrombolysis, 2013, ~$220M), PneumRx (lung volume reduction coils, 2014, ~$475M), Galil Medical (cryoablation, 2016, ~$110M), Biocompatibles International (drug-eluting embolic beads, 2010, ~$242M), and Protherics (specialty biopharmaceuticals/antidotes, 2008, ~$397M) — alongside smaller undisclosed bolt-ons such as Roxwood Medical (2017) and Novate Medical (2018).

The company's commercial model is a regulated medical device and specialty pharma go-to-market: it sells to hospitals, interventional radiologists, vascular surgeons, urologists, pulmonologists, and oncology centers globally, with an installed workforce of 1001-5000 employees supporting international sales, clinical education, and regulatory affairs. Pricing details are not publicly disclosed, consistent with typical med-tech B2B contracting through hospital procurement, GPOs, and reimbursement pathways. Leadership includes Founder Phillip Breech, CFO Duncan Kennedy, Chief Development Officer Jamie Heath, and General Manager Steve Baldwin, reflecting a functional operating structure spanning finance, product development, and commercial operations.

Name

BTG International

Legal name

Boston Scientific Corporation

Website

https://btgplc.com

Company type

Public

Founded year

1948

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Interventional Medicine Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Diagnostic Imaging Centers (621512)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

• Interventional medicine
• Interventional radiology
• Vascular therapy
• Medical device manufacturing
• Specialty pharmaceuticals

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Core offering

BTG International is a global healthcare company focused on Interventional Medicine, developing and commercializing medical devices and specialty pharmaceuticals used in minimally invasive procedures. The company's portfolio spans interventional oncology, vascular, and pulmonary therapies acquired through targeted M&A (including EKOS ultrasound-assisted thrombolysis, Galil Medical cryoablation, PneumRx lung coils, and Novate Medical IVC filters). Operations are headquartered in London, United Kingdom, with the entity now operating as part of Boston Scientific Corporation.

Differentiator

Problem solved

Functional benefit

Products and services

• EKOS Ultrasound-Assisted Thrombolysis System Medical device for ultrasound-assisted catheter-directed thrombolysis in patients with vascular thrombosis, used by interventional radiologists and vascular specialists.
• Galil Medical Cryoablation Systems Cryoablation medical devices for minimally invasive tumor destruction, used by interventional radiologists and oncologists.
• PneumRx Lung Coils Medical device portfolio targeting pulmonary intervention in emphysema/lung disease, used by interventional pulmonologists.
• Biocompatibles Drug-Eluting Beads Drug-eluting bead technology for transarterial chemoembolization used in interventional oncology, primarily for liver cancer treatment.
• Protherics Specialty Pharmaceuticals Specialty pharmaceutical products used as antidotes/therapies in interventional and acute care settings, serving hospitals and emergency care providers.
• Novate Medical IVC Filter Inferior vena cava (IVC) filter medical device for pulmonary embolism prevention, used by vascular intervention specialists.
• Roxwood Medical Vascular Devices Vascular intervention medical devices used by interventional radiologists and vascular surgeons.
• CellMed AG Products Cell therapy/biomedical products integrated into the interventional medicine portfolio.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Fusion Pharmaceuticals Inc.Strategic or Co-development Partner · 1 June 2024In June 2024, AstraZeneca Plc completed its acquisition of Fusion Pharmaceuticals Inc. for $2.5 billion to strengthen its radiopharmaceutical portfolio. This acquisition represents a significant strategic move in the radiopharmaceutical space for cancer treatment.

Recent moves6 records

Expansion highlights4 records

Direct peers

• AngioDynamics: AngioDynamics is a US-based interventional medical device company with overlapping product lines in ablation, embolization (embolic beads), and vascular access. Its oncology-focused NanoKnife and bead products compete directly with BTG's interventional oncology portfolio in similar hospital call points.
• Sirtex Medical: Sirtex is the most direct competitor to BTG's TheraSphere franchise, offering SIR-Spheres Y-90 resin microspheres for radioembolization of liver tumors. Both compete head-to-head in interventional oncology with comparable modalities, targeting the same hepatic oncology indications and specialist physician base.
• Penumbra, Inc. Penumbra develops interventional thrombectomy and embolization devices for stroke, peripheral vascular disease and venous thromboembolism. Its peripheral thrombectomy portfolio directly overlaps with BTG's EKOS ultrasound-assisted thrombolysis franchise, and both target the same interventional radiology and vascular surgery call points.
• Merit Medical Systems: Merit Medical manufactures single-use interventional devices including embolization particles, microcatheters, and oncology ablation tools that compete with BTG's LC Bead embolics and other interventional consumables. Both serve interventional radiologists globally through hospital purchasing channels.
• Teleflex Incorporated: Teleflex provides interventional access, vascular, and specialty pharmaceutical products, including catheter-based therapies that overlap with BTG's interventional portfolio. Both companies serve interventional radiology and vascular surgery customers through similar hospital supply channels.

Broad incumbents

• Stryker Corporation: Stryker operates interventional and surgical device franchises (neurovascular, spine, ENT, surgical instruments). It competes with several BTG product lines through overlapping hospital specialty call points and serves a similar procedural specialist base.
• Boston Scientific Corporation: Boston Scientific acquired BTG International in 2019 for ~$4.2B and is now the corporate parent. BSX operates an overlapping interventional medicine portfolio (peripheral intervention, endoscopy, neuromodulation, urology) and provides the commercial scale on which BTG's products now ride.
• Medtronic plc: Medtronic operates a large interventional portfolio including neurovascular, peripheral vascular, and oncology ablation devices. As a broad incumbent in interventional medicine, it competes with several BTG product lines (peripheral intervention, embolization) across the same hospital specialty channels.
• Novartis AG (Advanced Accelerator Applications / Pluvicto): Novartis, through its Advanced Accelerator Applications subsidiary and Pluvicto (Lu-177 PSMA-617) radioligand therapy, is the dominant force in therapeutic radiopharmaceuticals. It competes with BTG's TheraSphere Y-90 franchise for oncology budgets, though in adjacent (radioligand vs. radioembolization) modalities rather than identical indications.

Emerging players

• Inari Medical: Inari Medical is a high-growth pure-play in venous thromboembolism intervention (FlowTriever, ClotTriever), directly competing with BTG's EKOS catheter-directed thrombolysis in the PE and DVT markets. Both target interventional cardiologists, vascular surgeons, and IRs treating venous disease.

Market position

Weaknesses4 records

Competitive moat3 records

Customer concentration

• Xx.com/btg

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BTG International